Company Overview

Monogram Biosciences, Inc. provides products to treat infectious diseases, cancer, and other serious diseases. It offers HIV tests or assays, such as Trofile (HIV Tropism Assay), a molecular assay to identify the tropism of a patient’s HIV; Trofile DNA, a co-receptor tropism assay to apply the proven performance of Trofile(R) to cell-associated viral DNA; and PhenoSense GT to combine actual phenotype and genotype drug resistance to result in a single report. Its HIV tests or assays also comprise GenoSure MG, a genotypic HIV drug resistance test; PhenoSense Entry, a phenotypic test to measure susceptibility to entry inhibitors; PhenoSense Integrase, a phenotypic resistance assay to measure su...

Monogram Biosciences, Inc. provides products to treat infectious diseases, cancer, and other serious diseases. It offers HIV tests or assays, such as Trofile (HIV Tropism Assay), a molecular assay to identify the tropism of a patient’s HIV; Trofile DNA, a co-receptor tropism assay to apply the proven performance of Trofile(R) to cell-associated viral DNA; and PhenoSense GT to combine actual phenotype and genotype drug resistance to result in a single report. Its HIV tests or assays also comprise GenoSure MG, a genotypic HIV drug resistance test; PhenoSense Entry, a phenotypic test to measure susceptibility to entry inhibitors; PhenoSense Integrase, a phenotypic resistance assay to measure susceptibility to integrase inhibitors; Replication Capacity assays to measure HIV’s ability to make copies of itself or replicate; and PhenoSense HIV, a phenotypic HIV drug resistance test and a phenotypic test. It offers oncology products, such as VeraTag technology to accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases. It offers drug resistance tests for hepatitis C virus (HCV) and hepatitis B virus; GeneSeq for entry inhibitors (HIV envelope sequencing) assays; PhenoSense HIV and HCV assays; PhenoSense and GeneSeq for Integrase inhibitors assays; and PhenoScreen, a phenotypic screening assay to evaluate the activity of reverse transcriptase, integrase, or entry inhibitors. It offers molecular diagnostics and testing services for healthcare and pharmaceutical companies. The company was formerly known as ViroLogic, Inc. and changed its name to Monogram Biosciences, Inc. in September 2005. The company was incorporated in 1995 and is headquartered in South San Francisco, California. As of August 3, 2009, Monogram Biosciences, Inc. operates as a subsidiary of Laboratory Corp. of America Holdings.

Key Executives for Monogram Biosciences, Inc.

Similar Private Companies By Industry

Recent Private Companies Transactions